BioNexus Gene Lab Corp SEC filings BGLC

BioNexus Gene Lab Corp has 157 filings in SEC EDGAR's recent list, going back to Jan 29, 2019. Its latest annual report, Form 10-K, was filed on Apr 14, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 7, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
DEF 14A Proxy statement Dec 3, 2025 Dec 24, 2025
PRE 14A Preliminary proxy statement Nov 14, 2025 Nov 14, 2025
DEF 14A Proxy statement Feb 27, 2025 Mar 19, 2025
PRE 14A Preliminary proxy statement Feb 10, 2025 Feb 10, 2025
DEF 14A Proxy statement Sep 16, 2024 Oct 4, 2024
PRE 14A Preliminary proxy statement Sep 6, 2024 Sep 6, 2024
DEF 14C Information statement Feb 29, 2024 Feb 29, 2024
PRE 14C Filing Jan 26, 2024 Jan 26, 2024
DEF 14C Information statement May 17, 2023 May 16, 2023
DEF 14C Information statement Feb 21, 2023 Feb 21, 2023
PRE 14C Filing Feb 10, 2023 Feb 10, 2023

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
BGLC (Nasdaq)
Fiscal year ends
December 31
Incorporated in
WY
Headquarters
Kuala Lumpur
SEC filer status
, Emerging growth company
SEC CIK
1737523
Former names
BioNexus Gene Lab Coporation (until May 8, 2020)

Other Services-Medical Laboratories companies

All 29 Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.